GlassScriptPhysician profile
Imad S Mufarrij
NPI 1962514158
$3,072.59
in general payments reported to CMS, 2019-2025
25 companies · $625 in 2025
The $625 reported for 2025 was more than what 79% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $287 · 2021: $453 · 2022: $621 · 2023: $595 · 2024: $326 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,461 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,460.98 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $524.25 | 2019-2025 | |
| Pfizer INC. | $378.74 | 2020-2025 | |
| Mayne Pharma Commercial LLC | $272.17 | 2021-2025 | |
| Astellas Pharma US INC | $236.00 | 2023-2025 | Veozah, Myrbetriq |
| Therapeuticsmd, INC. | $197.74 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $180.66 | 2023-2025 | Myfembree, Gemtesa |
| Coopersurgical, INC. | $148.99 | 2019-2025 | Paragard T 380a, Summit Doppler, Mara Console |
| Sage Therapeutics, LLC | $134.81 | 2021-2025 | Zurzuvae |
| Organon LLC | $113.52 | 2022-2024 | Nexplanon |
| Myovant Sciences INC. | $111.96 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $100.60 | 2021-2022 | |
| Myriad Women'S Health, INC. | $98.29 | 2023 | Myrisk |
| Optumhealth Care Solutions, LLC | $94.96 | 2024-2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Bayer Healthcare Pharmaceuticals INC. | $88.80 | 2020-2025 | |
| Caldera Medical, INC | $67.77 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $66.87 | 2022 | |
| Evofem Biosciences, INC. | $48.70 | 2021-2022 | |
| Hologic Sales and Service, LLC | $43.64 | 2024-2025 | Aptima, Myosure Tissue Removal Device |
| Amgen INC. | $31.66 | 2020 | |
| Merck Sharp & Dohme LLC | $31.36 | 2020 | |
| Shield Therapeutics INC | $27.56 | 2025 | |
| Meditrina | $21.93 | 2022 | |
| Davol INC. | $19.96 | 2020 | |
| Ferring Pharmaceuticals INC. | $16.20 | 2019 | |
| Lupin INC. | $15.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imad Mufarrij listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.